CUSIP No.		GB0001662252 (Ordinary Shares)  132148107 (American Depositary Shares)

This Amendment No. 10 (this “Amendment”) further amends the Tender Offer Statement on Schedule TO initially filed with the SEC on May 23, 2006 by AstraZeneca PLC and its wholly-owned subsidiary, AstraZeneca, relating to the Offer. Unless otherwise defined herein, all capitalized terms shall have the meaning given to them in the Offer Document filed as Exhibit 99.(a)(1) hereto.

On June 30, 2006, AstraZeneca issued a press release announcing the close of the initial offer period and the commencement of the subsequent offer period.

As of the close of the initial offer period on June 29, 2006, valid acceptances of the Offer had been received in respect of 35,562,279 CAT Shares (including CAT Shares represented by 2,085,549 CAT ADSs), representing approximately 82.7%. of the CAT Shares to which the Offer relates. Including the 5,700,000 CAT Shares acquired by AstraZeneca since May 23, 2006, AstraZeneca has acquired, or received valid acceptances of the Offer in respect of, 41,262,279 CAT Shares (including CAT Shares represented by 2,085,549 CAT ADSs) in aggregate, representing approximately 95.95% of the CAT Shares to which the Offer relates. Including the 10,217,983 CAT Shares held by AstraZeneca prior to the commencement of the Offer Period, AstraZeneca has acquired, or received valid acceptances of the Offer in respect of, 51,480,262 CAT Shares (including CAT Shares represented by 2,085,549 CAT ADSs) in aggregate, representing 96.73% of the existing issued share capital of CAT. As at the close of the initial offer period, 30,814 ADSs were subject to a notice of guaranteed delivery period

The subsequent offer period is expected to remain open for acceptance until such time as the compulsory acquisition procedures referred to in Part II of the Offer Document are completed or until 3:00 p.m. (London time), 10:00 a.m. (New York City time) on September 22, 2006, whichever occurs earlier.

Given that AstraZeneca has received acceptances under the Offer in respect of, or otherwise acquired, more than 90.0% of CAT Shares to which the Offer relates, AstraZeneca intends to exercise its rights pursuant to the provisions of Schedule 2 of the Interim Regulations to acquire compulsorily, on the same terms as the Offer, the remaining CAT Shares (including shares underlying CAT ADSs) in respect of which the Offer has not been accepted.

This Amendment also amends the disclosure in Item 8 (“Interest in Securities of the Subject Company”) and Item 11 (“Interest in Securities of the Subject Company”) of Item 13 (“Information Required by Schedule 13E-3”) of the Schedule TO to reflect AstraZeneca’s beneficial ownership of 51,480,262 CAT Shares, representing approximately 96.7% of the entire issued share capital of CAT (or 51,511,076 CAT Shares, representing approximately 96.8% of the entire issued share capital of CAT, if CAT ADSs that are subject to the notice of guaranteed delivery period under the Offer are included). This Amendment also amends the Schedule 13D initially filed with the SEC on December 27, 2004, as subsequently amended and restated on May 15, 2006, to reflect the information set out below.

ITEM 8.     INTEREST IN SECURITIES OF THE SUBJECT COMPANY.

Item 8(a) has been amended to include the following:

(a)

As of June 29, 2006, AstraZeneca PLC beneficially owned an aggregate of 51,480,262 CAT Shares, representing approximately 96.7% of the entire issued share capital of CAT (or 51,511,076 CAT Shares, representing approximately 96.8% of the entire issued share capital of CAT, if CAT ADSs that are subject to the notice of guaranteed delivery period under the Offer are included).

(b)

On June 29, 2006, AstraZeneca PLC and AstraZeneca closed the initial offer period under the Offer, during which valid acceptances had been received in respect of 35,562,279 CAT Shares (including CAT Shares represented by 2,085,549 CAT ADSs), and such securities will be purchased pursuant to the Offer at a price of 1,320 pence per share. As at June 29, 2006, 30,814 CAT ADS were subject to the notice of guaranteed delivery period under the Offer and will be purchased on the same basis as the CAT Securities tendered into the Offer during the initial offer period. These purchases will be funded by existing cash balances and working capital of AstraZeneca PLC and AstraZeneca.